Venn Life Sciences () chief executive Tony Richardson says the biotech services company is focused on brining larger deals into its pipeline.
“We’re now frequently bidding for contracts worth £1mln-2mln in value, which is a step up from where we were 18 months ago,” said Richardson.
The firm told investors today that it expects revenues for the full year 2015 to be at least double the prior year, in which it had €4.9mln.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE